

Monday, November 19th 2018

	Session	Presenter	Running title
11:45-13:00	Lunch & registration		
13:00-14:50	Welcome and introduction	Anders Bjartell	
	State of the art	Mark Rubin	Towards understanding the genomic complexity of prostate cancer
		Sigrid Carlsson	Prostate cancer screening: the past, the present and the future
	Screening and early detection	Hans Lilja	A pre-specified marker model in blood for improved prediction of BCR, metastasis or death
		Henrik Grönberg	Improving the diagnostic pipeline of prostate cancer
14:50-15:50	Coffee and posters		
15:50-17:35	Preclinical prostate cancer research	Rebecka Hellsten	The STAT3 inhibitor galiellalactone inhibits the generation of MDSC-like monocytes by prostate cancer cells
		Ya-Fang Mei	A novel oncolytic adenovirus as vector for prostate cancer treatment
		Yang Jin	IRE1 α -XBP1s pathway promotes prostate cancer by activating c-Myc signaling
		Yvonne Ceder	Functional in vivo screening identifies microRNAs driving metastatic dissemination of prostate cancer cells to bone marrow
		Malin Hagberg Thulin	Pre-clinical investigations of enzalutamide in bone metastatic castration resistant prostate cancer (CRPC)
		Britta Söderkvist	Hedgehog inhibition impairs tumor growth in castration resistant prostate cancer
		Kirsi Ketola	Cellular Plasticity and Reprogramming in Lethal Neuroendocrine Prostate Cancer
from 19:00	Reception and dinner at Hipp, Malmö		

Tuesday, November 20th 2018

	Session	Presenter	Running title
9:00-10:20	Selected prostate cancer research and clinical studies	Yahia al Jebari	The risk of prostate cancer in men undergoing assisted reproduction
		Henrik Ugge	The influence of prostatic Cutibacterium acnes infection on serum levels of IL6 and CXCL8 in prostate cancer patients
		Susan Evans Axelsson	PIONEER - big data in prostate cancer
		Anders Widmark	Ultrahypofractionation for prostate cancer: Outcome from the Scandinavian phase 3 HYPO-RT-PC trial
		Ola Bratt	PCASTT/SPCG-17 – A randomised trial of MRI based active surveillance with standardised triggers for biopsy and treatment
10:20-11:20	Coffee and posters		
11:20-12:05	Radiology and imaging	Anders Örbom	Distribution of radioactivity inside tumors in animal models of radionuclide therapy of prostate cancer
		Adalsteinn Gunnlaugsson	Using MR-scanner for improving radiotherapy of prostate cancer
		Lars Edenbrandt	New Imaging Biomarkers in PET/CT based on Deep Learning
12:05-13:10	Lunch		
13:10-14:25	Liquid biopsies and blood biomarkers	Ingrid Guldvik	Lrg1 as a non-invasive biomarker for improved precision in prostate cancer management
		Andreas Josefsson	Hyaluronidase treatment reveals a different gene expression profile of circulating tumor cells enriched with antibody based methods in prostate cancer patients
		Johan Lindberg	Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis
		Marie Lundholm	High expression of S100A9 and S100A12 in peripheral blood mononuclear cells is associated with poor outcome in metastatic prostate cancer
		Jonas Nilsson	Circulating biomarkers with the ability to predict and monitoring therapeutic response in CRPC
14:25-14:55	Coffee		
14:55-16:20	Tissue biomarkers	Marthe Løvf	Multifocal primary prostate cancer exhibits high degree of genomic heterogeneity
		Ann Erlandsson	M2 macrophages and regulatory T cells in lethal prostate cancer
		Elin Thysell	Prostate cancer bone metastasis subtypes
		Maja Marklund	Spatial Transcriptomics Analysis of Castration-Resistant Prostate Cancer
		Thorgerdur Palsdottir	Are Prostate Specific-Antigen (PSA) and age associated with the risk of ISUP grade 1 prostate cancer? Results from 78,216 individual biopsy cores in 6,518 men
	Concluding remarks	Anders Bjartell	
from: 17:30	Post meeting event at Clarion hotel Malmö:	Eleni Efstathiou	Translating clinical evidence into individualized treatment decisions in metastatic prostate cancer
Special invitation by JANSSEN. For more information contact Charlotte Wickström: cwickstr@its.jnj.com			